Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2a,Condition 2b,Condition 3a,Condition 3b,Condition 4,Condition 5,Condition 6 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,3,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.4433,,0.0971,0.1683,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),54606,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,11,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.2754,,0.0423,0.1405,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),54617,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,3,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.3813,,0.3139,0.5437,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56015,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,7,,CMO:0000727,logarithm of the concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-8.4059,,0.0971,0.257,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56026,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,12,,CMO:0000728,maximum contractile force per wet weight of aorta,,,,1.495,g/mg,0.1214,0.4205,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours),55762,potassium ion (80 mmol/l) (for 0.2 hours),phenylephrine (10 umol/l) (for 0.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,11,,CMO:0000728,maximum contractile force per wet weight of aorta,,,,1.2745,g/mg,0.0632,0.2094,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours),55778,potassium ion (80 mmol/l) (for 0.2 hours),phenylephrine (10 umol/l) (for 0.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,12,,CMO:0000728,maximum contractile force per wet weight of aorta,,,,1.3092,g/mg,0.1424,0.4932,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours),57308,controlled sodium content diet (4 %) (for 21 days),,potassium ion (80 mmol/l) (for 0.2 hours),phenylephrine (10 umol/l) (for 0.2 hours),,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,17,,CMO:0000728,maximum contractile force per wet weight of aorta,,,,1.1588,g/mg,0.0862,0.3556,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours),57324,controlled sodium content diet (4 %) (for 21 days),,potassium ion (80 mmol/l) (for 0.2 hours),phenylephrine (10 umol/l) (for 0.2 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,11,,CMO:0000724,concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,2.2861,E-7mole,0.5617,1.8628,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),55868,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,11,,CMO:0000724,concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.7537,E-7mole,0.0803,0.2662,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),55884,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,12,,CMO:0000724,concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,1.5748,E-7mole,0.1821,0.6309,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),56494,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,16,,CMO:0000724,concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,1.4626,E-7mole,0.272,1.088,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),56510,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,11,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is moles/liter,,-8.0876,,0.0842,0.2793,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),55249,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,11,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is moles/liter,,-7.7336,,0.0681,0.2258,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),55265,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,12,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is moles/liter,,-8.281,,0.2148,0.7441,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56079,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,17,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is moles/liter,,-8.4942,,0.1608,0.6629,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),56095,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,12,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,70.75,%,7.1902,24.9076,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),54754,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,16,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,60.875,%,4.6654,18.6615,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),54770,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,11,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,71.1818,%,5.5396,18.3729,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),57198,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,11,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,54.4545,%,4.6717,15.4943,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),57214,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,11,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-7.1478,,0.047,0.1559,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),55615,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,11,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-6.774,,0.1132,0.3753,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),55599,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,12,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-6.8472,,0.066,0.2287,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),56889,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,16,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-6.9859,,0.1101,0.4404,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),56905,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,3,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,12.3333,%,3.383,5.8595,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),55042,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,10,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,20.3,%,4.3539,13.7683,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),55053,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,3,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,13.3333,%,7.9652,13.7961,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),55070,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,7,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,10.2857,%,1.8736,4.957,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),55081,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,3,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,6,%,3.0551,5.2915,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),55130,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,10,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,14.7,%,3.4093,10.7812,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),55141,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,3,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,15.3333,%,4.0961,7.0946,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),56270,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours), 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,7,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,18,%,3.5254,9.3274,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),56281,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours), 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,3,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,30,%,2.3094,4.0,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours),57133,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,7,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,31.8571,%,2.6675,7.0576,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours),57144,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours) 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,3,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,38.6667,%,4.3333,7.5056,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours),57165,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours), 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,10,,CMO:0000733,hypoxia-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,52.7,%,2.5779,8.152,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) then controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours) then controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours) then controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours),57176,phenylephrine (1 umol/l) ,,controlled oxygen content physiological salt solution perfusate (95 %) (for 0.2 hours),,controlled oxygen content physiological salt solution perfusate (10 %) (for 0.3 hours),,controlled oxygen content physiological salt solution perfusate (5 %) (for 0.3 hours),controlled oxygen content physiological salt solution perfusate (0 %) (for 0.3 hours), 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,3,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,93.6667,%,6.3333,10.9697,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56302,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,7,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,99.1429,%,0.7047,1.8645,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56313,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,3,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,100,%,0.0,0.0,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56462,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,11,,CMO:0000732,sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,99.4545,%,0.2817,0.9342,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56473,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,3,,CMO:0000726,concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.0377,10E-7mol/l,0.0074,0.0128,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),55732,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,11,,CMO:0000726,concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.0556,10E-7mol/l,0.0055,0.0182,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),55743,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,,,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,3,,CMO:0000726,concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.0699,10E-7mol/l,0.0478,0.0827,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56227,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasodilation trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,7,,CMO:0000726,concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,0.0469,10E-7mol/l,0.0135,0.0356,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (1 umol/l) (for 0.2 hours) then sodium nitroprusside (0-3 umol/l) and drug dose time series (for 1 hours),56238,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (1 umol/l) (for 0.2 hours),,sodium nitroprusside (0-3 umol/l) ,drug dose time series (for 1 hours),,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0098,umol/l,0.002,0.0066,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54648,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,11,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0211,umol/l,0.0036,0.012,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54664,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,female,84 days to 70 days,12,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0109,umol/l,0.0028,0.0095,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54880,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,, 522,PhysGen Vascular data,vasoconstriction trait,Moms and pups used in studies were fed Teklad,RS:0000321,FHH-Chr 12BN/Mcwi,male,84 days to 70 days,17,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0062,umol/l,0.0013,0.0055,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 21 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),54896,controlled sodium content diet (4 %) (for 21 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),,,,,